As regulations and requirements for transparent interactions between pharmaceutical, medical device and biotechnology companies (collectively “life sciences organizations” or “LSOs”), and healthcare professionals (“HCPs”) continue to evolve, certain patterns are emerging. It is becoming increasingly important to protect prescribers and companies by ensuring that transactions are commercially reasonable and FMV compliant.
Service: Advisory and Business Consulting
Kicking the tires: Why pre-LOI due diligence is so important
LBMC shares about the importance of Pre-LOI due diligence during the M&A process.
Physician Practices Considering a Private Equity Transaction
Ask these essential questions before selling to a private equity… Read more »
How to Reduce The “No Show” Rate at Your Physician Practice
A physician’s time is a valuable asset. Here are tips on how to reduce your practice’s “no show” rate.
eDiscovery or Digital Forensics?
Here’s a brief explanation and comparison of both, as well as a few key reasons that it’s important to know the difference and choose the right experts carefully.
Healthcare and the R&D Tax Credit Go Hand-In-Hand
Due to the high-volume of innovation and disruption in the healthcare industry, R&D tax credit opportunities may arise when least expected.
What to Consider When Conducting an Urgent Care Center Valuation
Chris Lovin, Practice Leader of LBMC’s Business Valuation/Litigation Support explains what you should consider when conducting an Urgent Care Center Valuation.
Call Coverage Arrangements
Here are a few key concepts and questions to consider when structuring and supporting an on-call arrangement.
Merger and Acquisition Due Diligence Best Practices
When potential acquirers look at a prospective business, inventory quantity and valuation are common risk areas. What follows here are some questions for leadership to ask to determine if they’re ready for an opportunity to sell.